Everything drug pricing and policy, every day
And two useful correctives to the White House’s myopic views on how international reference pricing works in the real world
And a podcast recommendation on the coming challenges in oncology
And industry gets a win in a 340B “STD loophole” case
And there is bipartisan consensus on the most divisive issue in health care [sic]
Plus, launching the quarterly Apex tracker of CEO earnings commentary
And Elizabeth Warren’s inquiry into TrumpRx asks the exact questions I’m interested in
And the votes are in on the “healthcare” vs “health care” debate ...
And I need your vote on an issue of huge significance
